BioNTech SE is a German biotechnology company based in Mainz. It develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. The company is working to develop the BNT161b2 RNA vaccine against SARS-CoV-2 with Pfizer and Fosun.
About BioNTech in brief
BioNTech SE is a German biotechnology company based in Mainz. It develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. In 2020, BioNTech’s RNA vaccine candidate for preventing COVID-19 infections, BNT162b2, was in Phase III clinical trials in the United States. On 2 December 2020, temporary Human Medicines Regulations authorisation was granted by the United Kingdom government for BNT 162b2 vaccinations within the UK.
The company is working to develop the BNT161b2 RNA vaccine against SARS-CoV-2 with Pfizer and Fosun. In 2019, six clinical studies were initiated using four therapeutic platforms and covering two classes of compounds. A total of ten product candidates were processed in eleven clinical studies in 2019. With a valuation of around 3.1 billion euros based on the issue price of 15 dollars per share, Bio NTech established itself in the top group of the German biotech scene.
You want to know more about BioNTech?
This page is based on the article BioNTech published in Wikipedia (as of Dec. 07, 2020) and was automatically summarized using artificial intelligence.
